PMID- 17393011
OWN - NLM
STAT- MEDLINE
DCOM- 20070604
LR  - 20070329
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 97
IP  - 4
DP  - 2007 Apr
TI  - The management of thrombosis in pregnancy: role of low-molecular-weight heparin.
PG  - 505-13
AB  - Fatal pulmonary embolism remains the most common cause of mortality among 
      pregnant women in many Western countries. The physiological changes of pregnancy 
      produce a hypercoagulable state that increases the risk of venous thromboembolism 
      (VTE). Women with inherited or acquired thrombophilias are at particularly high 
      risk of VTE during pregnancy, and thromboprophylaxis may be advisable in some 
      cases. Thrombophilia is also associated with complications of pregnancy, 
      including fetal loss, pre-eclampsia, intra-uterine growth restriction, and 
      placental abruption. The antithrombotic agents available for the prevention and 
      treatment of VTE during pregnancy, and pregnancy complications, include 
      unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and aspirin. 
      Vitamin K antagonists are contra-indicated in pregnancy. Low-dose aspirin may 
      have a role in the prevention of some pregnancy complications, although its 
      safety in early and late pregnancy is uncertain. The efficacy and safety of LMWHs 
      have been demonstrated for the prevention and treatment of VTE in pregnancy. 
      These agents are increasingly being used in place of UFH, which is associated 
      with a higher incidence of side effects compared with LMWH, in addition to the 
      need for regular laboratory monitoring. Evidence is also emerging to support the 
      use of LMWH in the prevention of recurrent fetal loss, although further trials 
      are needed to explore the role of LMWHs in this indication and in the prevention 
      of other complications of pregnancy.
FAU - Kher, Andre
AU  - Kher A
AD  - Euthemis, Saint-Mande, Paris, France.
FAU - Bauersachs, Rupert
AU  - Bauersachs R
FAU - Nielsen, Jorn Dalsgaard
AU  - Nielsen JD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/adverse effects/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/adverse effects/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy/etiology/*prevention & 
      control
MH  - Pregnancy Complications, Hematologic/drug therapy
MH  - Pulmonary Embolism/drug therapy/prevention & control
MH  - Risk Factors
MH  - Thromboembolism/drug therapy/prevention & control
MH  - Thrombophilia/complications/drug therapy
MH  - Thrombosis/*drug therapy/etiology/*prevention & control
MH  - Venous Thrombosis/drug therapy/prevention & control
RF  - 93
EDAT- 2007/03/30 09:00
MHDA- 2007/06/05 09:00
CRDT- 2007/03/30 09:00
PHST- 2007/03/30 09:00 [pubmed]
PHST- 2007/06/05 09:00 [medline]
PHST- 2007/03/30 09:00 [entrez]
AID - 07040505 [pii]
PST - ppublish
SO  - Thromb Haemost. 2007 Apr;97(4):505-13.